Last reviewed · How we verify

DAO supplement — Competitive Intelligence Brief

DAO supplement (DAO supplement) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Enzyme supplement. Area: Gastroenterology / Allergy / Histamine Intolerance.

marketed Enzyme supplement Histamine (substrate); diamine oxidase enzyme Gastroenterology / Allergy / Histamine Intolerance Small molecule Live · refreshed every 30 min

Target snapshot

DAO supplement (DAO supplement) — Nanjing First Hospital, Nanjing Medical University. DAO (diamine oxidase) supplement provides exogenous enzyme to break down histamine in the gastrointestinal tract, reducing histamine accumulation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DAO supplement TARGET DAO supplement Nanjing First Hospital, Nanjing Medical University marketed Enzyme supplement Histamine (substrate); diamine oxidase enzyme
Pancrease MT 10.5, or MT 21 Pancrease MT 10.5, or MT 21 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. phase 3 Pancreatic enzyme supplement

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Enzyme supplement class)

  1. Nanjing First Hospital, Nanjing Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DAO supplement — Competitive Intelligence Brief. https://druglandscape.com/ci/dao-supplement. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: